18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

ABSTRACTAn 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdomi...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical nuclear medicine Vol. 43; no. 5; pp. e142 - e144
Main Authors:	Eshghi, Naghmehossadat, Lundeen, Tamara F, MacKinnon, Lea, Avery, Ryan, Kuo, Phillip H
Format:	Journal Article
Language:	English
Published:	United States Copyright Wolters Kluwer Health, Inc. All rights reserved 01-05-2018
Subjects:	Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Merkel Cell - diagnostic imaging Carcinoma, Merkel Cell - drug therapy Fluorodeoxyglucose F18 Humans Male Positron Emission Tomography Computed Tomography Radiopharmaceuticals Skin Neoplasms - diagnostic imaging Skin Neoplasms - drug therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACTAn 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0363-9762 1536-0229
DOI:	10.1097/RLU.0000000000002051